Progress of 1H FY14 andMid-term Outlook
Achieve Sustainable and Profitable GrowthTerumo Corporation
President and Representative Director
Yutaro Shintaku
November 5, 2014

Roadmap to FY16
Secure a foothold in FY13-14*OPM Target in FY16

Write off assets of certain
businesses

20%
17.5%
17%

Achieve FY14 guidanceTarget OPM 20% by FY16FY13Actual

FY14
Guidance

FY16
Target*Excl. amortization of goodwill and intangibles withrelated to the acquisition of CaridianBCT© Terumo Corporation

2014/11/5

2/13

Progress in 1H FY14
Continued to write off assets of certain businesses from FY13
 Closed the factory for blood bags in Changchun, China (Sep.)
 Transform product portfolio of Hospital and Laboratory Business in Europe (Oct.)Made a strong start to achieve FY14 guidanceAim to achieve OPM* 20% by reinforcing profit management
under “Business-led Management”*Excl. amortization of goodwill and intangibles withrelated to the acquisition of CaridianBCT© Terumo Corporation

2014/11/5

3/13

Ongoing Global Industry Consolidation
Current

FY1310

1 J&J
2 Medtronic
3 Baxter
4 Fresenius
5 Covidien
6 Abbott7 Stryker8 BD
9 Boston
10 B.Braun
11 St. Jude
12 Olympus
13 Terumo- CareFusion

20 （$BN）

Medtronic
1 + Covidien
2 J&J
3 BaxterBD
4 + CareFusion
5 Fresenius
6 Abbott7 Stryker
Zimmer8 + Biomet
9 Boston
10 B.Braun
11 St. Jude
12 Olympus
13 Terumo© Terumo Corporation

1020 （$BN）

2014/11/5

4/13

Terumo’s Mid-term Outlook
1. Continue to launch excellent usability products
2. Expand presence of overseas IS business
3. Launch “Ultimaster”
4. “Double pipeline” to achieve continuous growth
5. Strengthen IS new products R&D in California, U.S.
6. Enter into regenerative and cell therapy market© Terumo Corporation

2014/11/5

5/13

1. Continue to Launch Excellent Usability ProductsReceived FY2014 Good Design AwardMisago<Evaluation>
 Conformable to vessels flexibly
and increased treatment accuracy
 Easy to grip

Medisafe Finetouch Dispo（Lancet for measuring blood glucose）<Evaluation>
 Easy to hold and simple procedure Expected to lower risk of pricking
fingers and less pain

© Terumo Corporation

2014/11/5

6/13

2. Expand Presence of Overseas IS Business
EuroPCR 2014 main entrance

Exceeding coronary intervention market growth
FY06→FY13 CAGR
Coronary intervention market+2%Sales
Terumo overseas IS business +18%($M)

Market($M)

1600

12000

1400
1200

10000

Coronary intervention market*

Terumo’s boothTerumo

8000

1000

6000

800
600

4000

400

Ultimaster and OFDI live at main arena

Terumo overseas IS business
2000

200

00
FY06

FY07

FY08

FY09

FY10

FY11

FY12

FY13

*Researched by Terumo© Terumo Corporation

2014/11/5

7/13

3. Launch Ultimaster: Surpass Nobori’s Initital Sales Record
Great contribution in sales and profits(Unit)

2500
2000
1500
Nobori
Ultimaster

1000
500
0M1

M2

M3M4M5M6

Nobori: launched in Apr, 2008
Ultimaster: launched in May, 2014
© Terumo Corporation

2014/11/5

8/13

4. “Double Pipeline” to Achieve Continuous Growth
Bioresorbable scaffold

Bioresorbable scaffold:
Joint developmentwith ART in France
2008

Nobori2014

UltimasterHybrid type DES

Abluminal coating
Bioresorbable polymer

Thin strut
High comformability
to blood vessel© Terumo Corporation

2014/11/5

9/13

5. Strengthen IS new products R&D in California, U.S.

Early Stage

Full-scale
Development

Clinical Trial

Utilize resourcesof Silicon Valley

Leverage R&D infrastructureof MicroVention

Reinforce organizationof clinical affairs in U.S.

Participate in incubation
activities within Fogarty
Institute for Innovation
Invested in EMPⅡCarotid stent（CASPER）
Drug coated balloon (DCB)Next generation peripheral stentSpeedy launchStrategic regulatory filingfor therapeutic devices

Carotid stent（CASPER）

Drug coatedballoon (DCB)© Terumo Corporation

2014/11/5

10/13

6. Enter into Regenerative and Cell Therapy Market
Cardiac regenerative therapy using cell sheets Filed an application for the manufactureand sales approval of autologous skeletal
myoblast sheets The first step towards clinical use of the world’s
first product to be used as a cardiac regenerative
therapy from Japan

October 31, 2014
The Nikkei (1)Terumo BCT: Expand business for cell therapy
 Provide devices for collection, expansion of stem cells© Terumo Corporation

2014/11/5

11/13

Terumo BCT Initiatives for Infection Disease Convalescent Plasma(Trima and Mirasol)Collect plasma and improvesafety of blood transfusion

Componentcollection
Pathogenreductiontechnology

 Study feasibility to use pathogen
reduction technology (Mirasol) toinactivate virus for vaccine production

October 22, 2014The Nikkei (6)Ebola virus

 Prevent expansion of Dengue fever,etc. (Mirasol)Prevent expansion of infection from bloodtransfusion© Terumo Corporation

2014/11/5

12/13

IR Contact
Terumo Corporation
Corporate Communication (IR) Dept.
E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, the forward-looking statements including
financial projections are based upon our assumptions using information available to us at thetime and are not intended to be guarantees of future events or performance. Accordingly, it
should be noted that actual results may differ from those forecasts on projections due tovarious factors. Factors affecting to actual results include, but are not limited to, changes in
economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state ofcompetition.
The market share information in this presentation is partly derived from our own independentresearch.

© Terumo Corporation

2014/11/5

13/13